BioCentury
ARTICLE | Clinical News

China approves Linzess for IBS-C

January 18, 2019 8:04 PM UTC

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said China's National Medical Products Administration approved Linzess linaclotide to treat irritable bowel syndrome with constipation (IBS-C). The company expects to launch the guanylate cyclase C (GCC; GUCY2C) agonist in China with partner AstraZeneca plc (LSE:AZN; NYSE:AZN) in 2H19...